Adicet Bio Inc

Adicet Bio, Inc. is a clinical-stage, pre-revenue biotechnology company. It discovers and develops allogeneic (off-the-shelf) gamma delta T cell therapies engineered with chimeric antigen receptors (CARs), as well as in vivo CAR-T therapies, for autoimmune diseases, hematologic malignancies and solid tumors.

Its pipeline includes:
- **Prula-cel (prulacabtagene leucel, formerly ADI-001):** The lead candidate, a CD19-targeting gamma delta CAR-T being evaluated in a Phase 1 study in systemic lupus erythematosus with or without lupus nephritis. Pivotal lupus nephritis study start-up is underway, and a systemic sclerosis cohort is also being studied.
- **ADI-212:** A gene-edited, off-the-shelf candidate for metastatic castration-resistant prostate cancer. It holds an FDA-cleared IND and Fast Track Designation.
- **In vivo CAR-T programs:** Preclinical programs targeting multiple myeloma, non-Hodgkin's lymphoma and solid tumors.

The company funds operations through its cash and investment holdings and has no product revenue. Updated Nov 5, 2026